Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan

Tatsuro Tajiri, Ryota Sozaki, Yoshiaki Kinoshita, Sakura Tanaka, Yuhki Koga, Aiko Suminoe, Akinobu Matsuzaki, Toshiro Hara, Tomoaki Taguchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The mass screening (MS) for neuroblastoma (NB) at 6 months of age in Japan was discontinued in 2004. This study assessed the risks and benefits of MS based on an analysis of NB detected before or after discontinuation of MS in Japan. Methods: The clinical features and Brodeur's genetic type based on MYCN, DNA ploidy, and other genetic aberrations were assessed in 113 NB patients (20 cases after and 93 cases [55 MS cases] before the discontinuation of MS) older than 6 months treated at one institution since 1985. Results: The 20 patients with NBs detected after MS was discontinued ranged in age from 7 to 67 months, 12 patients were stage 4, and 11 patients would have been detected at 6 months of age if they had undergone MS. The Brodeur's genetic type of these 20 patients showed that 30% (6/20) were type 1 (low risk), 55% (11/20) were type 2A (intermediate risk), and 15% (3/20) were type 2B (high risk). Of 93 patients with NB detected before MS was discontinued, 60% (56/93) were type 1, 18% (17/93) were type 2A, and 22% (20/93) were type 2B. Among the type 2A patients, 82% (9/11) of the patients detected after MS was discontinued showed stage 4, whereas only 50% (9/18) of those diagnosed before MS was discontinued were stage 4. The genetic analysis using single nucleotide polymorphism (SNP) array for type 2A showed that the pattern of genetic aberration was equivalent in those detected either before or after MS was discontinued. Conclusions: There was a decrease of type 1 and an increase of type 2A NB in patients after MS was discontinued in Japan. These results suggest that most of the type 1 detected by MS has regressed, and most of the type 2A detected by MS has appeared sporadically as advanced NB in patients older than 1 year.

Original languageEnglish
Pages (from-to)2253-2257
Number of pages5
JournalJournal of Pediatric Surgery
Volume44
Issue number12
DOIs
Publication statusPublished - Dec 1 2009

Fingerprint

Mass Screening
Neuroblastoma
Japan
Ploidies
Single Nucleotide Polymorphism

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan. / Tajiri, Tatsuro; Sozaki, Ryota; Kinoshita, Yoshiaki; Tanaka, Sakura; Koga, Yuhki; Suminoe, Aiko; Matsuzaki, Akinobu; Hara, Toshiro; Taguchi, Tomoaki.

In: Journal of Pediatric Surgery, Vol. 44, No. 12, 01.12.2009, p. 2253-2257.

Research output: Contribution to journalArticle

Tajiri, Tatsuro ; Sozaki, Ryota ; Kinoshita, Yoshiaki ; Tanaka, Sakura ; Koga, Yuhki ; Suminoe, Aiko ; Matsuzaki, Akinobu ; Hara, Toshiro ; Taguchi, Tomoaki. / Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan. In: Journal of Pediatric Surgery. 2009 ; Vol. 44, No. 12. pp. 2253-2257.
@article{e8b452ae1b994656b5c721788a9d897c,
title = "Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan",
abstract = "Purpose: The mass screening (MS) for neuroblastoma (NB) at 6 months of age in Japan was discontinued in 2004. This study assessed the risks and benefits of MS based on an analysis of NB detected before or after discontinuation of MS in Japan. Methods: The clinical features and Brodeur's genetic type based on MYCN, DNA ploidy, and other genetic aberrations were assessed in 113 NB patients (20 cases after and 93 cases [55 MS cases] before the discontinuation of MS) older than 6 months treated at one institution since 1985. Results: The 20 patients with NBs detected after MS was discontinued ranged in age from 7 to 67 months, 12 patients were stage 4, and 11 patients would have been detected at 6 months of age if they had undergone MS. The Brodeur's genetic type of these 20 patients showed that 30{\%} (6/20) were type 1 (low risk), 55{\%} (11/20) were type 2A (intermediate risk), and 15{\%} (3/20) were type 2B (high risk). Of 93 patients with NB detected before MS was discontinued, 60{\%} (56/93) were type 1, 18{\%} (17/93) were type 2A, and 22{\%} (20/93) were type 2B. Among the type 2A patients, 82{\%} (9/11) of the patients detected after MS was discontinued showed stage 4, whereas only 50{\%} (9/18) of those diagnosed before MS was discontinued were stage 4. The genetic analysis using single nucleotide polymorphism (SNP) array for type 2A showed that the pattern of genetic aberration was equivalent in those detected either before or after MS was discontinued. Conclusions: There was a decrease of type 1 and an increase of type 2A NB in patients after MS was discontinued in Japan. These results suggest that most of the type 1 detected by MS has regressed, and most of the type 2A detected by MS has appeared sporadically as advanced NB in patients older than 1 year.",
author = "Tatsuro Tajiri and Ryota Sozaki and Yoshiaki Kinoshita and Sakura Tanaka and Yuhki Koga and Aiko Suminoe and Akinobu Matsuzaki and Toshiro Hara and Tomoaki Taguchi",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.jpedsurg.2009.07.050",
language = "English",
volume = "44",
pages = "2253--2257",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan

AU - Tajiri, Tatsuro

AU - Sozaki, Ryota

AU - Kinoshita, Yoshiaki

AU - Tanaka, Sakura

AU - Koga, Yuhki

AU - Suminoe, Aiko

AU - Matsuzaki, Akinobu

AU - Hara, Toshiro

AU - Taguchi, Tomoaki

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Purpose: The mass screening (MS) for neuroblastoma (NB) at 6 months of age in Japan was discontinued in 2004. This study assessed the risks and benefits of MS based on an analysis of NB detected before or after discontinuation of MS in Japan. Methods: The clinical features and Brodeur's genetic type based on MYCN, DNA ploidy, and other genetic aberrations were assessed in 113 NB patients (20 cases after and 93 cases [55 MS cases] before the discontinuation of MS) older than 6 months treated at one institution since 1985. Results: The 20 patients with NBs detected after MS was discontinued ranged in age from 7 to 67 months, 12 patients were stage 4, and 11 patients would have been detected at 6 months of age if they had undergone MS. The Brodeur's genetic type of these 20 patients showed that 30% (6/20) were type 1 (low risk), 55% (11/20) were type 2A (intermediate risk), and 15% (3/20) were type 2B (high risk). Of 93 patients with NB detected before MS was discontinued, 60% (56/93) were type 1, 18% (17/93) were type 2A, and 22% (20/93) were type 2B. Among the type 2A patients, 82% (9/11) of the patients detected after MS was discontinued showed stage 4, whereas only 50% (9/18) of those diagnosed before MS was discontinued were stage 4. The genetic analysis using single nucleotide polymorphism (SNP) array for type 2A showed that the pattern of genetic aberration was equivalent in those detected either before or after MS was discontinued. Conclusions: There was a decrease of type 1 and an increase of type 2A NB in patients after MS was discontinued in Japan. These results suggest that most of the type 1 detected by MS has regressed, and most of the type 2A detected by MS has appeared sporadically as advanced NB in patients older than 1 year.

AB - Purpose: The mass screening (MS) for neuroblastoma (NB) at 6 months of age in Japan was discontinued in 2004. This study assessed the risks and benefits of MS based on an analysis of NB detected before or after discontinuation of MS in Japan. Methods: The clinical features and Brodeur's genetic type based on MYCN, DNA ploidy, and other genetic aberrations were assessed in 113 NB patients (20 cases after and 93 cases [55 MS cases] before the discontinuation of MS) older than 6 months treated at one institution since 1985. Results: The 20 patients with NBs detected after MS was discontinued ranged in age from 7 to 67 months, 12 patients were stage 4, and 11 patients would have been detected at 6 months of age if they had undergone MS. The Brodeur's genetic type of these 20 patients showed that 30% (6/20) were type 1 (low risk), 55% (11/20) were type 2A (intermediate risk), and 15% (3/20) were type 2B (high risk). Of 93 patients with NB detected before MS was discontinued, 60% (56/93) were type 1, 18% (17/93) were type 2A, and 22% (20/93) were type 2B. Among the type 2A patients, 82% (9/11) of the patients detected after MS was discontinued showed stage 4, whereas only 50% (9/18) of those diagnosed before MS was discontinued were stage 4. The genetic analysis using single nucleotide polymorphism (SNP) array for type 2A showed that the pattern of genetic aberration was equivalent in those detected either before or after MS was discontinued. Conclusions: There was a decrease of type 1 and an increase of type 2A NB in patients after MS was discontinued in Japan. These results suggest that most of the type 1 detected by MS has regressed, and most of the type 2A detected by MS has appeared sporadically as advanced NB in patients older than 1 year.

UR - http://www.scopus.com/inward/record.url?scp=71649115402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649115402&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2009.07.050

DO - 10.1016/j.jpedsurg.2009.07.050

M3 - Article

VL - 44

SP - 2253

EP - 2257

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 12

ER -